ImmuneRegen BioSciences announced this week that it has appointed Ivan Rich to its advisory board. The company said that Rich's experience as the founder, chairman, and CEO of HemoGenix, a research laboratory specializing in stem cell applications, is expected to benefit ImmuneRegen as it focuses on research and product development of its drug candidate, the adult stem cell-active compound Homspera.
In addition to his responsibilities at HemoGenix, Rich is also an adjoint professor of biology at the University of Colorado at Colorado Springs.
Znomics announced this week that Nikolaus Trede will join its scientific advisory board.
Trede is an assistant professor in the department of pediatrics at the University of Utah School of Medicine.
Trede and his team, in collaboration with researchers at the Oregon-based zebrafish shop, will develop proprietary T-cell disease assays in the zebrafish. These assays, based on endogenous T-cell markers, will then be used to screen the university's compound library to identify leads to be further developed for clinical testing (see News Scan, this issue).
Chris Brodie has joined the North Carolina Biotechnology Center as vice president of corporate communications, the center announced this week.
Brodie was previously an associate editor of American Scientist magazine.